Related Experiment Video

Updated: Aug 9, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

[Ethnic differences in apolipoprotein B levels in hyperlipidemia in Russian and Kirghiz populations]

E M Mirrakhimov, A M Noruzbaeva, O S Lunegova

    Terapevticheskii Arkhiv
    |August 31, 2004
    PubMed

    Insights

    Apolipoprotein B (apo-B) levels were higher in Russian patients with primary hyperlipidemia (PHL) compared to Kirghiz patients. Apo-B is an independent risk factor for coronary heart disease (CHD) in Kirghiz, while low HDLP cholesterol is a risk factor in Russians.

    Area of Science:

    • Cardiovascular Medicine
    • Lipidology
    • Human Genetics

    Context:

    • Primary hyperlipidemia (PHL) is a dyslipidemic condition affecting lipid metabolism.
    • Ethnic variations in cardiovascular disease (CVD) risk factors are significant in population health.
    • Apolipoprotein B (apo-B) is a key lipoprotein implicated in atherosclerosis and coronary heart disease (CHD).

    Purpose:

    • To compare apolipoprotein B (apo-B) levels and coronary heart disease (CHD) risk factors between Russian and Kirghiz populations with primary hyperlipidemia (PHL).
    • To identify independent risk factors for CHD within these distinct ethnic groups.

    Summary:

    • Patients with PHL were assessed for lipid profiles, including low-density lipoprotein (LDLP) cholesterol, high-density lipoprotein (HDLP) cholesterol, triglycerides, and apo-B.
    • Russians exhibited significantly higher mean LDLP cholesterol and apo-B levels than Kirghiz patients.
    • Multifactorial regression analysis identified apo-B as an independent CHD risk factor in the Kirghiz, whereas low HDLP cholesterol was identified in Russians.

    Impact:

    • Findings highlight ethnic-specific differences in lipid profiles and CHD risk factors among individuals with PHL.
    • This research underscores the importance of tailored risk assessment strategies for cardiovascular disease prevention in diverse populations.
    • Understanding these variations can inform targeted interventions to mitigate CHD risk in specific ethnic groups.
    Abstract

    More Related Videos

    Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate11:13

    Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate

    Published on: May 9, 2019

    Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

    Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

    Published on: January 28, 2021

    Related Concept Videos

    Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

    Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

    Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
    Principles of Pharmacogenetics: Types of Genetic Variants01:27

    Principles of Pharmacogenetics: Types of Genetic Variants

    The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
    Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

    Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

    The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

    Blood Studies for Cardiovascular System III: Serum Lipid Profile

    Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
    Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
    Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...